Halozyme Therapeutics

HALO · NASDAQ

$124.37+$1.87 (+1.53%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $122.50

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Employees: 423
Headquarters: San Diego, California
Listed: Jan 30, 2003
Sector: Health Care
Industry: Biotechnology
Website: halozyme.com

Leadership

Halozyme Therapeutics executives
Name	Title	Since	Age
Jeffrey Henderson	—	—	60
Helen Torley	—	2014	62
Nicole LaBrosse	—	—	42
Cortney Caudill	—	—	49
Mark Snyder	—	—	58
James Lang	—	—	60
Bernadette Connaughton	—	—	67
Barbara Duncan	—	—	60
Mahesh Krishnan	—	—	54
Moni Miyashita	—	—	69
Matthew Posard	—	—	57
Tram Bui	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $1.40B total revenue

By product

Royalties$867.84M62.1%
Product sales, net$376.44M27.0%
Revenues under collaborative agreements$152.33M10.9%

By region

United States$822.98M58.9%
Switzerland$276.41M19.8%
Belgium$217.52M15.6%
Japan$46.37M3.3%
All other foreign$33.33M2.4%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Halozyme Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Takeda Pharmaceutical	Supplier and customer	JP	0.65
Eisai	Supplier and customer	JP	0.51
argenx ARGX.BR	Supplier and customer	NL	0.50
Takeda Pharmaceutical Company Limited TKPHF	Customer	—	0.42
Bristol-Myers Squibb BMY	Supplier and customer	US	0.40
Johnson & Johnson JNJ	Supplier and customer	US	0.30
AstraZeneca AZN.L	Supplier and customer	GB	0.25
Nektar Therapeutics NKTR	Supplier	US	0.17
Horizon Therapeutics HZNP	Supplier and customer	IE	0.13
Eli Lilly and Company LLY	Customer	US	0.12

Similar companies

Companies in the same industry as Halozyme Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.